Acumen Pharmaceuticals, Inc. (ABOS)

Profile

https://acumenpharm.com

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead program centers on sabirnetug (ACU193), an investigational immunotherapy designed to selectively target toxic soluble amyloid beta oligomers, which are believed to contribute to Alzheimer’s pathology. Acumen’s work is aimed at disease-modifying treatment approaches rather than symptom management, with its research and clinical programs concentrated on early symptomatic and mild Alzheimer’s disease. Headquartered in Newton, Massachusetts, Acumen Pharmaceuticals operates within the neuroscience and biotechnology sectors, where it plays a specialized role in advancing antibody-based therapies and diagnostics for neurodegenerative disease.